Bioasis Technologies jumps 23% on funding agreement of up to C$10M

  • A pre-clinical, research-stage biopharmaceutical company, Bioasis Technologies (OTCQB:BIOAF +23.3%) announces that it has entered into a convertible security funding agreement dated June 22, 2021 with Lind Global Macro Fund, LP, an entity managed by The Lind Partners.
  • Under the terms of the agreement, company

Recommended For You

Comments (1)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.